Arbutus Biopharma (ABUS) Net Cash Flow (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Net Cash Flow for 14 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 669.27% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 123.09% YoY) and the FY2025 annual result came in at -$18.3 million, down 281.65% from the prior year.
• Net Cash Flow climbed to $5.7 million in Q1 2026 per ABUS's latest filing, from -$4.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for ABUS reached as high as $19.7 million in Q2 2024 and fell as low as -$34.0 million in Q2 2022.
• A 5-year average of -$5.0 million and a median of $315000.0 in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow sank 219.9% — and 2026, when it surged 669.27%.
• Year by year, Net Cash Flow stood at $6.8 million in 2022, then advanced by 28.98% to $8.7 million in 2023, then tumbled by 48.32% to $4.5 million in 2024, then slumped by 197.43% to -$4.4 million in 2025, then surged by 229.7% to $5.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $5.7 million, -$4.4 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.